Compare Fresenius Kabi Onco. with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs CIPLA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. CIPLA FRESENIUS KABI ONCO./
CIPLA
 
P/E (TTM) x 22.1 32.0 69.2% View Chart
P/BV x 3.1 4.5 68.9% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 FRESENIUS KABI ONCO.   CIPLA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
CIPLA
Mar-20
FRESENIUS KABI ONCO./
CIPLA
5-Yr Chart
Click to enlarge
High Rs176586 30.1%   
Low Rs79357 22.0%   
Sales per share (Unadj.) Rs37.7207.0 18.2%  
Earnings per share (Unadj.) Rs5.118.6 27.4%  
Cash flow per share (Unadj.) Rs6.733.2 20.3%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5195.5 21.8%  
Shares outstanding (eoy) m158.23806.35 19.6%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x3.42.3 148.4%   
Avg P/E ratio x25.025.3 98.6%  
P/CF ratio (eoy) x18.914.2 133.2%  
Price / Book Value ratio x3.02.4 124.1%  
Dividend payout %021.5 0.0%   
Avg Mkt Cap Rs m20,135379,912 5.3%   
No. of employees `0001.225.8 4.5%   
Total wages/salary Rs m70330,270 2.3%   
Avg. sales/employee Rs Th5,176.26,459.6 80.1%   
Avg. wages/employee Rs Th610.41,171.2 52.1%   
Avg. net profit/employee Rs Th699.6580.2 120.6%   
INCOME DATA
Net Sales Rs m5,963166,949 3.6%  
Other income Rs m183,442 0.5%   
Total revenues Rs m5,981170,391 3.5%   
Gross profit Rs m1,43032,060 4.5%  
Depreciation Rs m25811,747 2.2%   
Interest Rs m-261,974 -1.3%   
Profit before tax Rs m1,21621,782 5.6%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3426,312 5.4%   
Profit after tax Rs m80614,995 5.4%  
Gross profit margin %24.019.2 124.9%  
Effective tax rate %28.129.0 97.1%   
Net profit margin %13.59.0 150.5%  
BALANCE SHEET DATA
Current assets Rs m5,102117,038 4.4%   
Current liabilities Rs m2,38543,931 5.4%   
Net working cap to sales %45.643.8 104.0%  
Current ratio x2.12.7 80.3%  
Inventory Days Days15096 156.7%  
Debtors Days Days11385 133.2%  
Net fixed assets Rs m5,148107,424 4.8%   
Share capital Rs m1581,613 9.8%   
"Free" reserves Rs m6,556156,018 4.2%   
Net worth Rs m6,732157,630 4.3%   
Long term debt Rs m95223,693 4.0%   
Total assets Rs m10,388236,626 4.4%  
Interest coverage x-45.812.0 -380.3%   
Debt to equity ratio x0.10.2 94.1%  
Sales to assets ratio x0.60.7 81.4%   
Return on assets %7.57.2 104.7%  
Return on equity %12.09.5 125.8%  
Return on capital %14.612.8 113.7%  
Exports to sales %74.533.0 225.3%   
Imports to sales %24.80-   
Exports (fob) Rs m4,44155,175 8.0%   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29856,036 9.5%   
Fx outflow Rs m1,7726,764 26.2%   
Net fx Rs m3,52549,272 7.2%   
CASH FLOW
From Operations Rs m1,27430,685 4.2%  
From Investments Rs m-1,2041,040 -115.7%  
From Financial Activity Rs m-196-29,488 0.7%  
Net Cashflow Rs m-1262,340 -5.4%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 81.0 20.8 389.4%  
Indian inst/Mut Fund % 0.3 12.2 2.5%  
FIIs % 9.6 23.7 40.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 9.1 26.2 34.7%  
Shareholders   42,599 161,166 26.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   NEULAND LABS  PROCTER & GAMBLE HEALTH  GSK PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Maruti Suzuki's Production in April, IDBI Bank's Strategic Divestment, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended higher yesterday. Benchmark indices witnessed buying tracking positive cues from global peers.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - ELDER PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS